Drug Development

MS Research Roundup: October 16, 2015

Highlights from the 2015 meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona: B-Cell Bashing Ocrelizumab; New Outcome Measure for Daclizumab

Items of interest in multiple sclerosis research from around the Web...

Clinical Research, Drug Development, Meetings

PodBlog: Status of Stem Cell Therapies for MS

Episode 55 of the MSDF podcast features Michael Levy, MD, PhD, of Johns Hopkins University School of Medicine, who discusses the status of regenerative stem cell therapies for multiple sclerosis.

Episode 55 of the MSDF podcast is out. Check it out. The podcast features an interview with...

Clinical Research, Drug Development, Laboratory Research, Meetings, People

Studies Propose Vaccination for Troublemaking Virus

A classic immune tactic shows promise against PML, a rare but dangerous side effect of some MS treatments

A common virus found in many healthy people can cause a rare but potentially lethal...

Clinical Research, Drug Development, Laboratory Research

Episode 51 with Dr. Luke Lairson on discovery of small molecules to induce remyelination

MSDF interviews Luke Lairson PhD of The Scripps Research Institute and the California Institute for Biomedical Research about a drug screen to find potential remyelination compounds and the strategy for researching their potential usefulness as candidate drugs to repair tissue damage in MS.

Links to articles and other resources mentioned in Episode 51

Drug Development, Laboratory Research, Methods

The Orion Conference: Turning Big Data Into Knowledge

A conference in Cambridge, Massachusetts, outlined progress and challenges in turning computational modeling into actionable knowledge in MS and other brain disorders

I’d like to tell you about a conference that Orion Bionetworks hosted at the...

Clinical Research, Drug Development, Laboratory Research, Meetings, Methods

Refined Animal Model Led to Phenytoin Clinical Trial

In 2010, Professor David Baker was awarded an NC3Rs Project Grant to develop a...

An animal model that presents an alternative to EAE suggested a role for sodium channel blockers in neuroprotection. This led directly to a successful human trial of phenytoin, which was presented at last week’s AAN meeting.

Clinical Research, Drug Development, Laboratory Research, Meetings, Methods

How We Manage the Weekly List of MS Papers

Every Friday, MSDF editors use a curated PubMed search to link to every newly published MS-related paper. Here’s how we do it.

Each week, somewhere between 30 and 110 papers related to multiple sclerosis are...

Clinical Research, Drug Development, Laboratory Research, Methods

Seeking Answers for Progressive MS

An invitational meeting in Boston marks a step forward in a concerted international push to find effective therapies to target disease mechanisms, manage symptoms, and improve rehabilitation

A meeting in Boston early in March drew more than 80 scientists and clinical researchers to address...

Clinical Research, Drug Development, Laboratory Research, Meetings

Help Keep MSDF Alive!

Do you find MSDF invaluable? If so, please help us continue by making a tax-deductible donation NOW.

If you’re reading this message, it’s because you’re one of the 16,000 unique...

Clinical Research, Drug Development, Laboratory Research, Meetings, Methods, People

MS Research Roundup: February 18, 2015

Carbon Nanoparticles for MS; #HackMS Stands for Big Data and More; Restoring Myelin in Irradiated Brains; Lemon Verbena for MS Tea Time

Items of interest to multiple sclerosis researchers from around the Web...

Clinical Research, Drug Development, Laboratory Research

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu